Latest News and Press Releases

ZUG, Switzerland, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing...

ZUG, Switzerland, Feb. 08, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting of earnout shares and associated removal of restrictions on these ordinary shares. ...

ZUG, Switzerland, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares...

ZUG, Switzerland, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Attached is a Notification of Major Changes in Voting Rights. Attachment Notification of Major Changes in Voting...

ZUG, Switzerland, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Attached is a Notification of Major Changes in Voting Rights. Attachment Notification of Major Changes in Voting...

Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential...

ZUG, Sviss, Jan. 06, 2025 (GLOBE NEWSWIRE) -- OCS-05 var öruggt og þoldist vel í samanburði við lyfleysu.Tölfræðilega marktækar framfarir á virkni samanborið við lyfleysu, m.a. fyrir þykkt sjónhimnu...

ZUG, Switzerland, Jan. 06, 2025 (GLOBE NEWSWIRE) -- OCS-05 showed a favorable safety and tolerability profile compared to placeboAchieved statistically significant results on key secondary efficacy...

ZUG, Switzerland, Jan. 04, 2025 (GLOBE NEWSWIRE) -- Attached is a Notification of Major Changes in Voting Rights, in relation to Brunnur vaxtarsjóður slhf‘s distribution of its shares in Oculis...

ZUG, Switzerland, Dec. 06, 2024 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company. Attachments ...